Pharmaron Beijing Co., Ltd.
300759.SZ
Shenzhen Stock Exchange30.57
CNY
-0.23
- -
Pharmaron Beijing Co., Ltd.
300759.SZ
(Shenzhen Stock Exchange)
Recent
price
30.57
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Pharmaron Beijing Co., Ltd. (300759.SZ/3759.HK) provides fully integrated research, development and manufacturing services for the life sciences industry, spanning drug discovery, preclinical and clinical development across small molecules, biologics and cell and gene therapy products. The company offers laboratory services including medicinal and synthetic chemistry, chemistry for new modalities such as oligonucleotides, peptides, antibodies and antibody-drug conjugates, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, computer-aided drug design, structural biology, in vitro biology, DMPK, in vivo pharmacology and compound management; chemistry, manufacturing and controls services encompassing API process development and production, material science, pre-formulation, formulation development and manufacturing, analytical development; clinical development services such as integrated radiolabelled science, early-stage and Phase I-IV clinical trials, clinical trial recruitment; safety assessment, integrated drug discovery and bioanalysis; and biologics and cell and gene therapy services comprising biologics laboratory and CDMO, cell and gene therapy laboratory and gene therapy CDMO. Founded in 2004 and headquartered in Beijing, China, Pharmaron operates over 21 R&D centers and manufacturing sites with more than 22,000 employees, serving clients in North America, Europe, Japan, Mainland China and internationally from facilities in China, the U.S. and the U.K. In October 2025, the company entered a definitive share purchase agreement to acquire 82.54% equity interest in Biortus Biosciences Co., Ltd., enhancing its capabilities in structural biology, complex protein production and analysis, protein science, biological assays, compound screening, protein crystallization, structure analysis and structure-based drug design to strengthen its end-to-end multi-modality platform.